Intrexon ROE 2012-2018 | XON

Current and historical return on equity (ROE) values for Intrexon (XON) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Intrexon ROE for the three months ending September 30, 2018 was -15.71%.
Intrexon ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-09-30 $-0.20B $0.56B -33.87%
2018-06-30 $-0.18B $0.57B -30.94%
2018-03-31 $-0.13B $0.63B -22.90%
2017-12-31 $-0.12B $0.55B -21.06%
2017-09-30 $-0.13B $0.55B -23.89%
2017-06-30 $-0.12B $0.57B -21.40%
2017-03-31 $-0.15B $0.55B -25.99%
2016-12-31 $-0.19B $0.57B -30.00%
2016-09-30 $-0.18B $0.61B -26.76%
2016-06-30 $-0.18B $0.63B -26.88%
2016-03-31 $-0.18B $0.68B -27.11%
2015-12-31 $-0.09B $0.71B -13.20%
2015-09-30 $-0.03B $0.73B -5.79%
2015-06-30 $-0.05B $0.49B -9.95%
2015-03-31 $-0.06B $0.65B -12.90%
2014-12-31 $-0.08B $0.41B -20.39%
2014-09-30 $-0.11B $0.38B -27.83%
2014-06-30 $-0.05B $0.39B -12.31%
2014-03-31 $-0.01B $0.43B -3.12%
2013-12-31 $-0.06B $0.38B -23.72%
2013-09-30 $-0.05B $0.39B -32.83%
2013-06-30 $-0.08B $0.21B -161.17%
2013-03-31 $-0.09B $0.00B inf%
2012-12-31 $-0.05B $0.00B -240.00%
Sector Industry Market Cap Revenue
Medical Medical Services $1.138B $0.231B
Intrexon Corporation is a biotechnology company. It provides synthetic biology services. The Company designs and produces modular DNA control systems and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery. Intrexon Corporation is based in Germantown, Maryland.
Stock Name Country Market Cap PE Ratio
Express Scripts Holding (ESRX) United States $55.382B 11.45
ICON (ICLR) Ireland $7.220B 22.63
PRA Health Sciences (PRAH) United States $6.479B 26.45
Charles River Laboratories (CRL) United States $6.010B 21.07
Premier (PINC) United States $5.056B 17.16
INC Research Holdings (SYNH) United States $4.514B 18.22
HealthEquity (HQY) United States $3.874B 75.72
Teladoc (TDOC) United States $3.587B 0.00
NovoCure (NVCR) Jersey $3.317B 0.00
AMN Healthcare Services Inc (AMN) United States $2.641B 18.12
BioTelemetry (BEAT) United States $2.149B 37.97
Medpace Holdings (MEDP) United States $1.902B 23.53
IKang Healthcare (KANG) China $1.412B 70.10
Healthways (TVTY) United States $1.070B 13.16
CareDx (CDNA) United States $1.067B 0.00
Natera (NTRA) United States $0.946B 0.00
China Cord Blood (CO) China $0.729B 20.00
Surgery Partners (SGRY) United States $0.612B 0.00
Apollo Medical Holdings (AMEH) United States $0.582B 0.00
Civitas Solutions (CIVI) United States $0.532B 9.66
Establishment Labs Holdings (ESTA) $0.485B 0.00
Interpace Diagnostics (IDXG) United States $0.029B 0.00
Cancer Genetics (CGIX) United States $0.015B 0.00
OpGen (OPGN) United States $0.008B 0.00
FORM Holdings (XSPA) United States $0.005B 0.00
Biocept (BIOC) United States $0.002B 0.00